Exelixis, Bristol-Myers Squibb team up to evaluate renal cell treatment drug
“The safety and efficacy data from the phase 1 clinical trial evaluating CABOMETYX in combination with Opdivo are consistent with the preclinical scientific rationale for combining these two therapeutic modalities,” Exelixis President and CEO Michael Morrissey said.
The evaluation will also include Yervoy (ipilimumab).
“This clinical development collaboration will provide the resources and collaborative framework to fully evaluate the potential for this combination, with and without Yervoy, in both late-stage pivotal and exploratory trials in a variety of forms of cancer," Morrissey said.
The clinical development program, which will be co-funded by the companies, is expected to include a Phase 3 pivotal trial in first-line renal cell carcinoma, with additional trials planned in bladder cancer, hepatocellular carcinoma, and potentially other tumor types.